Evidence map›Paper›PMID 40301260›Full record

ReviewAdvances in experimental medicine and biology2025

Non-hormonal Contraception: Current and Emerging Targets.

Jessica A Marinaro, Marc Goldstein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jessica A MarinaroDepartment of Urology, Weill Cornell Medicine, New York, NY, USA.
Marc GoldsteinDepartment of Urology, Weill Cornell Medicine, New York, NY, USA. mgoldst@med.cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a global need for effective, reversible contraception. While female hormonal options meet these criteria and are widely used, they are associated with side effects and may be contraindicated for women with certain pre-existing medical conditions. To meet the needs of women who cannot take or cannot tolerate these medications, several non-hormonal options are currently available, including copper intrauterine devices (IUDs), spermicides, and a new vaginal pH modulator (VPM). Several other options are currently in development, including vaginal rings, gels, and vaginally administered anti-sperm antibodies. For men, there are currently no contraceptive options available aside from condoms and vasectomy; however, several non-hormonal contraceptives targeting various aspects of sperm production and/or sperm function are currently under investigation. In this narrative review, we will discuss both the non-hormonal contraceptive methods currently available for women, as well as emerging non-hormonal medications, compounds, and devices for both genders.

Indexed as

ContraceptionFemaleHumansIntrauterine Devices, CopperMaleSpermatocidal AgentsSpermatocidal AgentsContraceptionMaleNon-hormonalSperm

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.